STOCK TITAN

Cabaletta Bio, Inc. - $CABA STOCK NEWS

Welcome to our dedicated page for Cabaletta Bio news (Ticker: $CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cabaletta Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cabaletta Bio's position in the market.

Rhea-AI Summary
Cabaletta Bio, Inc. has received FDA clearance for a Phase 1/2 study of its CD19-CAR T cell therapy, CABA-201, in patients with generalized myasthenia gravis (gMG). This marks the company's fourth Investigational New Drug (IND) application clearance for CABA-201. The clinical trial will include two parallel cohorts of six patients each, based on autoantibody status. The starting dose for the trial will be 1 x 10^6 cells/kg. Cabaletta plans to release initial clinical data from trials for lupus and myositis in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
-
Rhea-AI Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in three upcoming investor conferences in November. The CEO and President of the company will be present at these conferences to give fireside chats and engage in one-on-one meetings. The presentations will be available for live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
conferences
-
Rhea-AI Summary
Cabaletta Bio's third IND application for CABA-201 has been cleared by the FDA for a Phase 1/2 study in patients with systemic sclerosis (SSc). The company plans to initiate a clinical trial with two parallel cohorts. Three-month clinical data from initial patients treated with CABA-201 in lupus and/or myositis trials are on track to be reported by H1 2024. CABA-201 has the potential to slow or halt the progression of SSc, providing an important treatment option for patients. SSc affects approximately 88,000 patients in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
Rhea-AI Summary
Cabaletta Bio, Inc. to participate in two investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
conferences
-
Rhea-AI Summary
Cabaletta Bio, Inc. to participate in four investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
-
Rhea-AI Summary
Cabaletta Bio expands partnership with WuXi ATU for manufacturing of CABA-201 cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.68%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
conferences
Cabaletta Bio, Inc.

Nasdaq:CABA

CABA Rankings

CABA Stock Data

543.29M
39.40M
3.14%
102.27%
17.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
PHILADELPHIA

About CABA

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un